Comparison · NCT00659438-208f3f15
Vandetanib vs Placebo: Overall Survival (OS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib vs Placebo: Overall Survival (OS). Trial comparisons, record NCT00659438-208f3f15. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00659438-208f3f15
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.681 | 0.538 | 0.796 | wilson | |
| Risk in group 2 | 0.729 | 0.59 | 0.834 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0483 | -0.225 | 0.132 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.934 | 0.719 | 1.21 | log | |
| Odds ratio, group 1 over group 2 | 0.792 | 0.327 | 1.92 | log | |
| Number needed to treat, for one fewer participant with the outcome on Vandetanib than on Placebo | 20.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib | Bicalutamide 150mg + Vandetanib (ZD6474) 300mg | 32 | 47 | OG000 |
| Group 2 | Placebo | Bicalutamide 150mg + placebo | 35 | 48 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Overall Survival (OS)
- Description
To investigate the effect of vandetanib on overall survival. Patients alive at the time of the statistical analysis were censored at the time they were last known to be alive. Due to censored data, median overall survival in the placebo group cannot be calculated. OS defined as the number of participants who were alive.
- Time frame
- End of study (July 2011)
- Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
- NCT number
- NCT00659438
- Phases
- PHASE2
- Conditions
- Prostate Cancer
- Interventions
- ZD6474 (Vandetanib), Bicalutamide, Placebo
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2012-07-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00659438?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00659438-208f3f15